Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Factorial AssignmentIntervention Model Description: Participants will be randomized 1:1:1:1 in a blinded fashion to receive: Arm A: Placebo and Placebo Arm B: Lefitolimod and Placebo Arm C: Placebo and 3BNC117+10-1074 Arm D: Lefitolimod and 3BNC117+10-1074Masking: Double (Participant, Investigator)Masking Description: The participant and all study personnel who directly interact with study participants are blinded to study arm designation.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03837756
- Collaborators
- Aalborg University Hospital
- Odense University Hospital
- Rigshospitalet, Denmark
- Hvidovre University Hospital
- The Peter Doherty Institute for Infection and Immunity
- University of Utah
- Oslo University Hospital
- Investigators
- Principal Investigator: Ole S Søgaard, MD PhD Aarhus University Hospital
Get Well Soon